#### Alpha Globin Gene Copy Number and Exhaled Nitric Oxide in Healthy Black Adults

A. Parker Ruhl<sup>1,2</sup>, Jarrett M. Jackson<sup>1</sup>, Carlos J. Carhuas<sup>1</sup>, Jessica G. Niño de Rivera<sup>1</sup>, Michael P. Fay<sup>3</sup>, J. Brice Weinberg<sup>4</sup>, Loretta G. Que<sup>5</sup>, Hans C. Ackerman<sup>1</sup>

<sup>1</sup> Physiology Unit, Laboratory of Malaria and Vector Research, National Institute of Allergy and

Infectious Diseases, National Institutes of Health, Rockville, MD, United States

<sup>2</sup> Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health,

Bethesda, MD, United States

<sup>3</sup>Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National

Institutes of Health, Rockville, MD, United States

<sup>4</sup> Department of Medicine and Division of Hematology, Duke University School of Medicine and

Durham VA Medical Centers, Durham, NC, United States,

<sup>5</sup> Department of Medicine and Division of Pulmonary, Allergy, and Critical Care Medicine, Duke

University School of Medicine and Durham VA Medical Centers, Durham, NC, United States

Key words: Hemoglobin; Black American; fractional exhaled nitric oxide; alveolar epithelial cell; nitric oxide synthase

Word count: 997 / 1000

Tables and Figures: 2 tables and 1 figure

Corresponding author: Dr. A. Parker Ruhl, MD, MHS Building 10-Clinical Research Center, Rm. B3-4207 10 Center Dr., Bethesda MD, 20892-1684 parker.ruhl@nih.gov Tel: 240-669-5776 Fax: 301-480-0590

Author contributions: All listed authors meet ICJME recommendations for authorship criteria, including substantial contributions to the conception or design of the work (A.P.R., H.C.A., L.G.Q., J.B.W.); or the acquisition, analysis, or interpretation of data for the work (A.P.R., H.C.A., H.C.A., J.M.J., C.J.C., J.G.N., M. P. F., L.G.Q.); Drafting the work (A.P.R.) or revising it critically for important intellectual content and final approval of the version to be published (All).

### ABSTRACT (98/100)

The genetic determinants of fractional exhalation of nitric oxide (FeNO), a marker of lung inflammation, are understudied in Black populations. Alpha globin, which is polymorphic in Black populations, restricts nitric oxide signaling in arterial endothelial cells. We hypothesized that an alpha globin gene deletion would be associated with higher FeNO in a cross-sectional study of 643 healthy Black adults. We found that 30% were heterozygous and 4.7% were homozygous for the deletion. A prespecified additive genetic model found no association with FeNO; however, a post hoc recessive genetic model suggested that FeNO may be higher among homozygotes.

#### INTRODUCTION

Nitric oxide (NO) has numerous biological activities in the lung, serving as a bronchodilator, vasodilator, neurotransmitter, and inflammatory mediator. In asthmatic individuals, the fractional exhalation of nitric oxide (FeNO) is a validated measure of airway inflammation;<sup>1,2</sup> however, little is known about genetic factors influencing FeNO, particularly among Black populations.

Inducible NO synthase (*NOS2*) is the principal source of NO from airway epithelium, and inflammation increases its activity.<sup>3</sup> Genetic variation in the *NOS2* gene has been associated with FeNO levels in healthy individuals, but much of the variation in FeNO remains unexplained.<sup>4</sup> Recently, a new paradigm has emerged whereby NO signaling is restricted by globins expressed in the vascular endothelium that bind directly to NOS.<sup>5</sup> Globins are also expressed in human pseudostratified airway epithelial cells and alveolar epithelial cells, where beta globin colocalizes with endothelial nitric oxide synthase and regulates NO oxidation.<sup>6</sup> This suggests that globins regulate NO signaling not only in the vascular endothelium, but in the airway epithelium as well.

Alpha globin is expressed by the tandem duplicated genes *HBA1* and *HBA2*. A 3.7 kb alpha globin gene (*HBA*) deletion, common in Black Americans, is associated with increased NO signaling in small arteries and protection from kidney disease.<sup>7,8</sup> We hypothesized that healthy Black individuals carrying the alpha globin gene deletion would have increased NO signaling reflected as higher FeNO levels.

#### METHODS

Black healthy volunteers age 18-40 years were enrolled in a multi-center, cross-sectional cohort from 4 university sites near Durham, North Carolina from 2005 to 2008.<sup>9</sup> The protocol was approved by the Duke University Institutional Review Board (#Pro00004947). Age, sex, race, and ethnicity were self-reported. Only non-Hispanic African American participants were enrolled. Participants were asked to confirm they were healthy (i.e., no chronic illnesses or chronic use of

any medication except oral contraceptives); had no history of asthma, allergic rhinitis, hay fever, or atopic dermatitis; and were nonsmokers. Blood samples were obtained. *HBA* copy number was measured by droplet digital PCR (ddPCR) on genomic DNA. Total serum immunoglobulin-E (IgE) was measured. FeNO was measured in triplicate with a Sievers 280i Nitric Oxide Analyzer (GE Analytical Instruments, Boulder, Colo) according to American Thoracic Society recommendations.<sup>1</sup> A 50 mL/s flow rate was established against resistance to maintain 5 cmH<sub>2</sub>O oropharyngeal pressure.<sup>9</sup> Additional exclusion criteria for this analysis were: not consenting to future research and serum cotinine level  $\geq$ 25 ng/mL signifying active tobacco use.

For continuous measures, medians and 25<sup>th</sup> and 75<sup>th</sup> percentiles were calculated by *HBA* genotype. Group differences were assessed by Kruskal-Wallis test. Categorical variables were calculated as percentages and differences were assessed by Fisher's exact test. IgE and FeNO were log transformed due to skewness. The association of *HBA* genotype with FeNO was evaluated using multivariable linear regression employing a linear effect of *HBA* gene copy number with adjustment for age, sex, and total serum IgE levels. BMI was previously found not to be associated with FeNO in this cohort and was not included in the model.<sup>9</sup> Two post-hoc sensitivity analyses were performed: one evaluated *HBA* copy number as a categorical variable and one evaluated a recessive mode of inheritance in which the homozygous deletion genotype (-a/-a) was compared against all other genotypes (-a/aa, aa/aa, and aa/aaa).

#### RESULTS

Of 895 original study participants, 720 consented for future research and had DNA available for genotyping. Sixty-four participants were excluded due to high cotinine levels and 13 were excluded due to indeterminate *HBA* genotype. The remaining 643 participants were 35% male and had a median (25<sup>th</sup>,75<sup>th</sup>) age of 20 (19, 22) years, serum IgE level of 58.3 (22, 160) kU/L, and FeNO value of 20 (13, 31) ppb (Table 1).

4

*HBA* deletion was common with 30 (4.7%) -a/-a, 197 (30.6%) -a/aa, 405 (63%) aa/aa, and 8 (1.2%) aa/aaa genotypes. Median (25<sup>th</sup>, 75<sup>th</sup>) FeNO was 25 (18, 39) ppm in the -a/-a group, 20 (12, 27) ppm in the -a/aa group, 20 (13, 32) ppm in the aa/aa group, and 37 (9, 52) ppm in the aa/aaa group (Kruskal-Wallis p = 0.107; Table 1 and Figure 1). After adjustment for sex, age, and serum IgE, the coefficient for *HBA* copy number with FeNO was -0.005 (95% CI: -0.042, 0.033; p=0.811; Table 2) using the pre-specified additive genetic model. In post hoc sensitivity analyses, the association between the homozygous genotype -a/-a and FeNO was 0.099 (95% CI -0.007, 0.206; p = 0.066) when analyzed as a categorical variable and 0.107 (95% CI 0.003, 0.212; p = 0.045; Table 2) when analyzed using a recessive mode of inheritance.

#### DISCUSSION

Globins recently emerged as regulators of NO signaling in endothelial and epithelial cell contexts;<sup>5,6</sup> however, the impact of globin gene variation on exhaled NO remains unclear. We characterized a common *HBA* deletion in healthy Black individuals and examined the relationship between *HBA* copy number and FeNO. We found no association between *HBA* genotype and FeNO using a pre-specified additive genetic model; however, a post hoc analysis using a recessive mode of inheritance identified homozygosity for the *HBA* gene deletion to be associated with higher FeNO levels. This latter finding is consistent with the proposed mechanism that alpha globin limits the release of nitric oxide and suggests that lower alpha globin expression allows greater release of NO into airways. More work is needed to determine whether alpha globin binds iNOS in epithelial cells (as it binds eNOS in endothelial cells) and whether this interaction could be targeted to modulate lung inflammation.

Study strengths included the large cohort size, representation of a minority population, high frequency of the *HBA* gene deletion, a well-defined outcome measure, and adjustment for

5

serum IgE. Limitations included that the significant association was detected in a post hoc analysis, FeNO measurement was performed at a single flow rate that does not distinguish alveolar from bronchial NO sources,<sup>10</sup> and data on the potential confounders of recent upper respiratory tract infection and eosinophilic cationic protein were unavailable.<sup>9</sup>

In conclusion, homozygosity for a common *HBA* gene deletion appears to be associated with higher fractional exhalation of nitric oxide among healthy Black adults.

#### SOURCES OF FUNDING

The original study was supported by the Sandler Program for Asthma Research; ES011185 from the National Institute of Environmental Health Sciences; and MO1-RR-30 from the National Center for Research Resources, Clinical Research Centers Program, National Institutes of Health. The current analysis was supported in part by the Divisions of Intramural Research, National Institute of Allergy and Infectious Diseases project Al001150 (A.P.R., J.M.J, C.M.C, J.G.N., M.P. F., H.C.A), National Heart, Lung, and Blood Institute (NHLBI) project HL006196 (A.P.R., H.C.A.). This work was also funded in part by NHLBI grants NIH R01-HL107590 and R01HL153641 (L.G.Q.) and the Durham VA Medical Center Research Service (J.B.W.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID or NHLBI. The content of this publication does not necessarily reflect the view or policy of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the government. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.

#### DISCLOSURES

The authors have no conflicts of interest to declare. All co-authors have seen and agree with the contents of the manuscript and there is no financial interest to report. This article was previously published in abstract form. We certify that the submission is original work and is not under review at any other publication.

#### ACKNOWLEDGEMENTS

Several co-authors have new current affiliations, Jarrett Jackson is at the Vanderbilt University Medical Center, Nashville, TN, United States; Carlos Carhuas is at the Comprehensive Sickle Cell Disease Program, Children's National Medicine Center,

7

Washington, DC, United States; and Jessica Nino De Rivera is at the Columbia University

Vagelos College of Physicians and Surgeons, New York, NY, United States

### Table 1. Participant characteristics grouped by alpha globin genotype

	HBA genotype										
	All participants		-a/-a		-a/aa		aa/aa		aa/aaa		<i>P</i> value⁺
No. participants*		643	30	) (4.7%)	197	(30.6%)	40	8 (63%)	8	(1.2%)	
Male Sex, No. (%)	222	(35)	12	(40)	66	(34)	142	(35)	4	(50)	0.678
Age, years	20	(19,22)	20	(19,22)	20	(19,22)	20	(19,22)	19	(19,24)	0.833
Mean FeNO <sup>‡</sup> , ppb	20	(13,31)	25	(18,39)	20	(12,27)	20	(13,32)	37	(9,52)	0.107
Total IgE, IU/mL	58	(22,160)	28	(16,96)	66	(25,176)	57	(21,158)	36	(24,46)	0.125
Body mass index, kg/m2	27	(24,32)	28	(26,33)	27	(23,33)	26	(23,32)	27	(25,34)	0.778
Height, inches	168	(162,175)	170	(161,177)	168	(163,173)	168	(162,175)	168	(163,176)	0.961
Weight, kilograms	77	(65,92)	81	(69,93)	77	(67,93)	76	(65,91)	85	(74,101)	0.716
Systolic blood pressure, mmHg	117	(109,124)	117	(108,130)	117	(110,123)	117	(109,125)	127	(126,133)	0.242
Diastolic blood pressure, mmHg	68	(63,74)	68	(63,73)	67	(62,74)	68	(63,75)	79	(70,85)	0.703
Mean arterial pressure, mmHg	84	(79,90)	85	(80,88)	82	(79,89)	84	(80,91)	99	(91,100)	0.352

No. = number; FeNO = fractional exhaled nitric oxide; ppb = parts per billion; IgE =

Immunoglobulin E; IU = international unit; mL = milliliter; mmHg = millimeters of mercury; MAP =

mean arterial pressure. Values are median (25<sup>th</sup>, 75<sup>th</sup> percentile) except where otherwise indicated.

\* Total number of participants (n=643). Missing data are as follows: Sex (n=2, <1%); Age (n=13,

2%); Mean FeNO (n=4, <1%); Total IgE (n=25, 3.8%}; Body mass index and weight (n=4, <1%);

Systolic blood pressure, diastolic blood pressure, and mean arterial pressure (n=292, 45.4%).

<sup>†</sup> P values calculated for differences between groups by Kruskal-Wallis non-parametric analysis

of variance and for categorical variables p values were calculated as percentages within each

category and differences were assessed by Fischer's exact test.

<sup>‡</sup> Mean FeNO levels measured according to ATS recommendations (reported here as median

[25<sup>th</sup>, 75<sup>th</sup> percentile] of the mean recorded FeNO)

# Table 2. Multivariable regression analysis of HBA genotype and fractional exhaled nitric oxide

Multivariable linear regression model employing <i>HBA</i> genotype as an integer gene copy number							
	Beta Coefficient	95% Confidence Interval	P value				
HBA copy number, per copy	-0.005	(-0.042, 0.033)	0.811				
Age, per year	-0.001	(-0.006, 0.003)	0.587				
Male sex	0.122	(0.074, 0.170)	< 0.001				
Log₁₀ IgE	0.137	(0.098, 0.176)	< 0.001				

## Post hoc multivariable linear regression model employing *HBA* genotype with a recessive mode of inheritance

	Beta Coefficient	95% Confidence Interval	P value
HBA genotype, -a/-a	0.107	(0.003, 0.212)	0.045
Age, per year	-0.001	(-0.006, 0.003)	0.541
Male sex	0.120	(0.071, 0.166)	< 0.001
Log₁₀ IgE	0.140	(0.102, 0.181)	<0.001

HBA = alpha globin gene; No. = number; Log<sub>10</sub> = log base 10; IgE = immunoglobulin E

# Figure 1. Fractional exhaled nitric oxide levels in 634 Black individuals grouped by alpha globin genotype.

 $Log_{10}$  = log base 10; FeNO = fractional exhaled nitric oxide; aa/aa = alpha globin genotypes; ddPCR = droplet digital polymerase chain reaction. Bold lines represent 50<sup>th</sup> percentile and upper and lower box lines represent 25<sup>th</sup> and 75<sup>th</sup> percentiles for each genotype.



### REFERENCES

- Khatri SB, Iaccarino JM, Barochia A, Soghier I, Akuthota P, Brady A, Covar RA, Debley JS, Diamant Z, Fitzpatrick AM, Kaminsky DA, Kenyon NJ, Khurana S, Lipworth BJ, McCarthy K, Peters M, Que LG, Ross KR, Schneider-Futschik EK, Sorkness CA, Hallstrand TS, American Thoracic Society Assembly on Allergy, Immunology, and Inflammation. Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2021;204:e97– e109.
- 2. Jeppegaard M, Veidal S, Sverrild A, Backer V, Porsbjerg C. Validation of ATS clinical practice guideline cut-points for FeNO in asthma. *Respir Med*. 2018;144:22–29.
- 3. Roos AB, Mori M, Grönneberg R, Österlund C, Claesson H-E, Wahlström J, Grunewald J, Eklund A, Erjefält JS, Lundberg JO, Nord M. Elevated exhaled nitric oxide in allergenprovoked asthma is associated with airway epithelial iNOS. *PLoS One*. 2014;9:e90018.
- 4. Dahgam S, Modig L, Torinsson Naluai Å, Olin A-C, Nyberg F. Haplotypes of the inducible nitric oxide synthase gene are strongly associated with exhaled nitric oxide levels in adults: a population-based study. *J Med Genet*. 2014;51:449–454.
- 5. Straub AC, Lohman AW, Billaud M, Johnstone SR, Dwyer ST, Lee MY, Bortz PS, Best AK, Columbus L, Gaston B, Isakson BE. Endothelial cell expression of haemoglobin α regulates nitric oxide signalling. *Nature*. 2012;491:473–477.
- 6. Marozkina N, Smith L, Zhao Y, Zein J, Chmiel JF, Kim J, Kiselar J, Davis MD, Cunningham RS, Randell SH, Gaston B. Somatic cell hemoglobin modulates nitrogen oxide metabolism in the human airway epithelium. *Sci Rep.* 2021;11:15498.
- Denton CC, Shah P, Suriany S, Liu H, Thuptimdang W, Sunwoo J, Chalacheva P, Veluswamy S, Kato R, Wood JC, Detterich JA, Khoo MCK, Coates TD. Loss of alpha-globin genes in human subjects is associated with improved nitric oxide-mediated vascular perfusion. *Am J Hematol.* 2020. doi:10.1002/ajh.26058.
- 8. Ruhl AP, Jeffries N, Yang Y, Naik RP, Patki A, Pecker LH, Mott BT, Zakai NA, Winkler CA, Kopp JB, Lange LA, Irvin MR, Gutierrez OM, Cushman M, Ackerman HC. Alpha Globin Gene Copy Number Is Associated with Prevalent Chronic Kidney Disease and Incident End-Stage Kidney Disease among Black Americans. *JASN*. 2022;33:213–224.
- 9. Levesque MC, Hauswirth DW, Mervin-Blake S, Fernandez CA, Patch KB, Alexander KM, Allgood S, McNair PD, Allen AS, Sundy JS. Determinants of exhaled nitric oxide levels in healthy, nonsmoking African American adults. *Journal of Allergy and Clinical Immunology*. 2008;121:396-402.e3.
- 10. Linn WS, Rappaport EB, Eckel SP, Berhane KT, Zhang Y, Salam MT, Bastain TM, Gilliland FD. Multiple-flow exhaled nitric oxide, allergy, and asthma in a population of older children. *Pediatric Pulmonology*. 2013;48:885–896.